By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Quality of Life Adjustments Don’t Matter for Cancer Treatment Cost Effectiveness
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Medical Ethics > Quality of Life Adjustments Don’t Matter for Cancer Treatment Cost Effectiveness
Medical Ethics

Quality of Life Adjustments Don’t Matter for Cancer Treatment Cost Effectiveness

DavidEWilliams
DavidEWilliams
Share
2 Min Read
SHARE

In a paper in Expert Review of Pharmacoeconomics & Outcomes Research, Dan Greenberg from Ben-Gurion University of the Negev and Peter J. Neumann from the Center for the Evaluation of Value and Risk in Health conclude that when it comes to determining the cost effectiveness of cancer treatments, quality of life adjustments really don’t matter. Many countries, including the UK, Canada and Australia take cost-effectiveness into account when deciding whether to reimburse for a treatment. (In the US we’re doing our best to avoid that, but eventually the policy is likely to change.) Health economists like using quality-adjusted life years (QALYs) as outcome measures because they incorporate improvements in morbidity and mortality in a single measure. But methods for calculating QALYs are somewhat controversial, since accurate determination requires good measurements of patients’ health states, which is hard to accomplish. Different methods of obtaining this information have been shown to yield different results, so there is suspicion that the use of QALYs could result in inappropriate reimbursement decisions. The researchers analyzed 117 cancer-related studies that included both a cost per life-year (unadjusted for quality of life) and a QALY calculation. As it turns out these indicators are highly correlated. Reimbursement decisions for cancer treatment are really not impacted by how the QALY is calculated –or even whether it’s calculated at all. The authors speculate that using QALYs is likely to have the most impact in treatments for chronic conditions where there are sustained side effects from the treatments themselves.

TAGGED:quality of life treatment
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

eHealthMedical EthicsMedical RecordsPolicy & Law

Organization fined $418,000 for business associate HIPAA breach

May 10, 2018

Florida Board of Medicine Declares Arizona Homeopathic Doctor “Very, Very Dangerous”

October 26, 2015

Telemedicine Is Growing, But HIPAA Concerns Remain

May 3, 2016
Medical EthicsWellness

Steering Patients Away From Cyberchondria [INFOGRAPHIC]

July 20, 2016
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?